JHVEphoto / Shutterstock.com
12 May 2022Big PharmaMuireann Bolger
Israel targets Teva over MS drug royalties
The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
24 February 2022 Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
24 March 2020 Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
18 October 2022 Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.
Editor's picks
Editor's picks
Americas
24 February 2022 Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
24 March 2020 Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
18 October 2022 Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.
Americas
24 February 2022 Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
24 March 2020 Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
18 October 2022 Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.